eltrombopag olamine
Generic: eltrombopag olamine
Labeler: somerset therapeutics, llcDrug Facts
Product Profile
Brand Name
eltrombopag olamine
Generic Name
eltrombopag olamine
Labeler
somerset therapeutics, llc
Dosage Form
TABLET, FILM COATED
Routes
Active Ingredients
eltrombopag olamine 12.5 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
70069-837
Product ID
70069-837_ec6939e2-4f64-4edd-848c-83e73ffac433
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
ANDA
Application Number
ANDA219638
Listing Expiration
2027-12-31
Marketing Start
2026-01-14
Pharmacologic Class
Classes
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
70069837
Hyphenated Format
70069-837
Supplemental Identifiers
RxCUI
UPC
UNII
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
eltrombopag olamine (source: ndc)
Generic Name
eltrombopag olamine (source: ndc)
Application Number
ANDA219638 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 12.5 mg/1
Packaging
- 30 TABLET, FILM COATED in 1 BOTTLE (70069-837-01)
Packages (1)
Ingredients (1)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "ec6939e2-4f64-4edd-848c-83e73ffac433", "openfda": {"upc": ["0370069838013", "0370069840016", "0370069839010", "0370069837016"], "unii": ["4U07F515LG"], "rxcui": ["825421", "825427", "884617", "1245001"], "spl_set_id": ["604f663c-4933-402a-8105-5921713cf3c8"], "manufacturer_name": ["Somerset Therapeutics, LLC"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET, FILM COATED in 1 BOTTLE (70069-837-01)", "package_ndc": "70069-837-01", "marketing_start_date": "20260114"}], "brand_name": "Eltrombopag olamine", "product_id": "70069-837_ec6939e2-4f64-4edd-848c-83e73ffac433", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Breast Cancer Resistance Protein Inhibitors [MoA]", "Increased Megakaryocyte Maturation [PE]", "Increased Platelet Production [PE]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Thrombopoietin Receptor Agonist [EPC]", "Thrombopoietin Receptor Agonists [MoA]", "UGT1A1 Inhibitors [MoA]", "UGT1A3 Inhibitors [MoA]", "UGT1A4 Inhibitors [MoA]", "UGT1A6 Inhibitors [MoA]", "UGT1A9 Inhibitors [MoA]", "UGT2B15 Inhibitors [MoA]", "UGT2B7 Inhibitors [MoA]"], "product_ndc": "70069-837", "generic_name": "Eltrombopag olamine", "labeler_name": "Somerset Therapeutics, LLC", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Eltrombopag olamine", "active_ingredients": [{"name": "ELTROMBOPAG OLAMINE", "strength": "12.5 mg/1"}], "application_number": "ANDA219638", "marketing_category": "ANDA", "marketing_start_date": "20260114", "listing_expiration_date": "20271231"}